Jushi Holdings Past Earnings Performance
Past criteria checks 0/6
Jushi Holdings's earnings have been declining at an average annual rate of -7.2%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 35% per year.
Key information
-7.2%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 35.0% |
| Return on equity | n/a |
| Net Margin | -20.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jushi Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 259 | -54 | 101 | 0 |
| 30 Jun 24 | 263 | -59 | 100 | 0 |
| 31 Mar 24 | 265 | -71 | 106 | 0 |
| 31 Dec 23 | 269 | -65 | 110 | 0 |
| 30 Sep 23 | 278 | -188 | 125 | 0 |
| 30 Jun 23 | 286 | -221 | 139 | 0 |
| 31 Mar 23 | 292 | -195 | 155 | 0 |
| 31 Dec 22 | 284 | -202 | 155 | 0 |
| 30 Sep 22 | 273 | -53 | 151 | 0 |
| 30 Jun 22 | 255 | 40 | 139 | 0 |
| 31 Mar 22 | 230 | 31 | 122 | 0 |
| 31 Dec 21 | 209 | 20 | 112 | 0 |
| 30 Sep 21 | 176 | -144 | 85 | 0 |
| 30 Jun 21 | 147 | -213 | 69 | 0 |
| 31 Mar 21 | 114 | -225 | 56 | 0 |
| 31 Dec 20 | 81 | -211 | 41 | 0 |
| 30 Sep 20 | 55 | -71 | 43 | 0 |
| 30 Jun 20 | 33 | -37 | 44 | 0 |
| 31 Mar 20 | 18 | -40 | 42 | 0 |
| 31 Dec 19 | 10 | -31 | 35 | 0 |
| 30 Sep 19 | 5 | -19 | 28 | 0 |
| 30 Jun 19 | 1 | -25 | 21 | 0 |
| 31 Mar 19 | 1 | -15 | 13 | 0 |
| 31 Dec 18 | 1 | -20 | 11 | 0 |
Quality Earnings: JUSH is currently unprofitable.
Growing Profit Margin: JUSH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JUSH is unprofitable, and losses have increased over the past 5 years at a rate of 7.2% per year.
Accelerating Growth: Unable to compare JUSH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JUSH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: JUSH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.